ACUR — Acura Pharmaceuticals Income Statement
0.000.00%
HealthcareHighly SpeculativeMicro Cap
- $1.31m
- $1.45m
- $1.56m
Annual income statement for Acura Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2017 December 31st | 2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 2.97 | 0.41 | 2.66 | 3.57 | 1.56 |
Cost of Revenue | |||||
Gross Profit | 2.84 | 0.41 | — | — | — |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 8.19 | 4.03 | 5.98 | 4.33 | 2.24 |
Operating Profit | -5.22 | -3.62 | -3.33 | -0.758 | -0.679 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -5.82 | -3.84 | -3.77 | -1.21 | -0.879 |
Provision for Income Taxes | |||||
Net Income After Taxes | 20.9 | -3.84 | -3.77 | -1.21 | -0.879 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -5.68 | -3.84 | -3.77 | -1.21 | -0.879 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -5.68 | -3.84 | -3.77 | -1.21 | -0.879 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 1.32 | -0.196 | -0.044 | -0.017 | -0.024 |